Vivacta Bio and Grit Bio have secured FDA orphan drug designation for GT801 in autoimmune hemolytic anemia. Early findings from two patients showed complete responses following treatment with the investigational in vivo CAR-T therapy, which uses targeted lipid nanoparticles to generate CD19-directed immune cells inside the body.
Johnson & Johnson backs Sail Biomedicines’ in vivo CAR-T platform with $785 million in initial payments and a $2.58 billion buyout option.
T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.
CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone
CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.